icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
QNZ0tLZkr1tcVZyS